TEWKSBURY, MA / ACCESSWIRE / April 25, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) has acquired an additional 14.8 acres of land at its Cambridge Isotope Separations (CIS) Xenia, Ohio location. Mike Steiger, Vice President of Engineering and Project Execution for CIL, stated that the new land purchase will ensure easier access to utilities for future expansion..

马萨诸塞州特克斯伯里/ACCESSWIRE/2024年4月25日/剑桥同位素实验室公司（CIL）在俄亥俄州的剑桥同位素分离公司（CIS）Xenia收购了另外14.8英亩的土地。CIL工程和项目执行副总裁迈克·施泰格（MikeSteiger）表示，新购土地将确保未来扩建更容易获得公用设施。。

Cambridge Isotope Separations

剑桥同位素分离

This newly acquired land is situated to the west of the 20 acres purchased in 2017, which is currently the site of the North Star expansion project. This recently completed project will greatly increase 13C production and is in the startup phase. North Star is the largest 13C separation facility ever built in the world and will significantly increase CIL's capacity ensuring customer reliability for this stable isotope..

这片新收购的土地位于2017年购买的20英亩土地的西部，目前是北极星扩建项目的场地。这个最近完成的项目将大大增加13C的产量，目前正处于启动阶段。北极星是世界上有史以来建造的最大的13C分离设施，将大大提高CIL的能力，确保客户对这种稳定同位素的可靠性。。

The land acquired provides the business flexibility to expand in the future as the demand continues to grow worldwide in all applications. 'This investment shows CIL's commitment to innovation and growth for our customers,' said CEO Cliff Caldwell. 'CIL works closely with our diverse and global customers to develop and commercialize exciting, high-value applications for isotopically labeled compounds.

随着全球所有应用的需求持续增长，收购的土地为未来的业务扩展提供了灵活性。”首席执行官克利夫·考德威尔（CliffCaldwell）说，这项投资表明CIL致力于为客户创新和增长CIL与我们多样化的全球客户密切合作，为同位素标记化合物开发令人兴奋的高价值应用并将其商业化。

As these applications commercialize, our customers rely on CIL's ability to scale our chemistry quickly and reliably. This land acquisition assures we have the space to continue meeting their expectations and enable these technology advancements.'.

随着这些应用的商业化，我们的客户依赖CIL快速可靠地扩展我们的化学物质的能力。这次土地收购确保了我们有空间继续满足他们的期望，并实现这些技术进步。”。

The CIS facility has the world's largest 13C separation facility, is one of the world's largest 18O isotope-separation facilities and houses the largest commercial D2O re-enrichment columns in the world.

CIS设施拥有世界上最大的13C分离设施，是世界上最大的18O同位素分离设施之一，拥有世界上最大的商业D2O再富集柱。

Stable isotopes, particularly deuterium, have seen an increase in commercial-scale applications in the last few decades. These applications include pharmaceuticals, semiconductors, flat panel displays, and other high-technology fields. CIL has a three-year supply contract with one Canadian source for D2O, as well as three other sources, and holds an average of an 18-24-month supply in four of CIL locations to ensure the most reliable supply..

在过去的几十年中，稳定同位素，特别是氘，在商业规模上的应用有所增加。这些应用包括制药、半导体、平板显示器和其他高科技领域。CIL与加拿大的一个D2O来源以及其他三个来源签订了为期三年的供应合同，并在CIL的四个地点平均拥有18-24个月的供应，以确保最可靠的供应。。

About Cambridge Isotope Laboratories, Inc.

关于剑桥同位素实验室有限公司。

CIL is the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL subsidiary ABX in Dresden, Germany, is active in the development and commercialization of radio isotopic-labeled compounds for the diagnosis and treatment of cancers.

CIL是全球最大的稳定同位素和稳定同位素标记化合物制造商和全球供应商，用于研究、环境、新生儿、制药、医疗诊断、OLED和工业市场。CIL在德国德累斯顿的子公司ABX积极参与放射性同位素标记化合物的开发和商业化，用于癌症的诊断和治疗。

CIL is an operating business owned by Otsuka Pharmaceutical. The CIL business consists of two facilities in the Boston, Massachusetts, area; a large isotope-enrichment production plant in Xenia, Ohio; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit isotope.com..

CIL是大冢制药拥有的运营企业。CIL业务包括位于马萨诸塞州波士顿地区的两个设施；俄亥俄州塞尼亚的一家大型同位素富集生产厂；CIL中国；加拿大CIL；德国德累斯顿的ABX；和法国萨克雷的Eurisoto。有关CIL的更多信息，请访问同位素网站。。

Contact Information

联系方式

Crissy Krisko

Crissy Krisko

crissyk@isotope.com

crissyk@isotope.com

1.978.269.1930

1.978.269.1930

SOURCE: Cambridge Isotope Laboratories, Inc.

资料来源：剑桥同位素实验室有限公司。

View the original press release on newswire.com.

在newswire.com上查看原始新闻稿。